In younger and middle-aged individuals, CRP may be a measure of the evolving development of subclinical disease that is not identifiable by usual clinical measurement techniques. Years later, this evolving subclinical disease may lead to clinical disease. Thus, CRP again may not be in the causal pathway but rather a marker for the extent of unmeasured subclinical disease and its evolution over time. However, as above, there are possible mechanistic alternatives. Elevated CRP reflects an increased production of proinflammatory cytokines such as interleukin-6, which may be contributing to the pathophysiology of disease either directly 8 or indirectly through their relationships to other important components of inflammation, thrombosis, or fibrinolysis. 9, 10 It would be imprudent to jump to the conclusion that CRP and related acute-phase proteins are mechanistic risk factors for disease and to assume that lowering the CRP level will reduce the risk of disease, without the appropriate evidence to support such a position. Although the study of CRP and other acute-phase proteins is of considerable importance, we should recognize that at the present time there is no direct evidence that CRP is an independent mechanistic risk factor for cardiovascular disease. There is also no evidence that it is in the causal pathway, and it does not appear to be a marker of disease extent or severity. Finally, there is certainly no evidence that lowering CRP, or any acute-phase protein, will reduce the progression of underlying disease or the risk of future disease events.
